Prostaglandin D 2 (PGD 2 ) is released following exposure of asthmatics to allergen and acts via the adenylyl cyclase-coupled receptor for PGD 2 (DP receptor). In this study, it is reported that human eosinophils possess this receptor, which would be expected to inhibit their activation. In contrast, it was found that prostaglandin D 2 is a potent stimulator of eosinophil chemotaxis, actin polymerization, CD11b expression, and Lselectin shedding. These responses are specific for eosinophils, as neutrophils display little or no response to prostaglandin D 2 . They were not due to interaction with receptors for other prostanoids, as prostaglandins E 2 and F 2␣ , U46619 (a thromboxane A 2 analogue), and carbaprostacyclin (a prostacyclin analogue) displayed little or no activity. Furthermore, they were not shared by the selective DP receptor agonist BW245C and were not prevented by the selective DP receptor antagonist BWA868C, indicating that they were not mediated by DP receptors. In contrast, the prostaglandin D 2 metabolite 13,14-dihydro-15-oxoprostaglandin D 2 induced eosinophil activation but did not stimulate DP receptor-mediated adenosine 3,5-cyclic monophosphate (cAMP) formation. These results indicate that in addition to the classic inhibitory DP 1 receptor, eosinophils possess a second, novel DP 2 receptor that is associated with PGD 2 -induced cell activation. These 2 receptors appear to interact to regulate eosinophil responses to PGD 2 , as blockade of DP 1 receptor-mediated cAMP production by BWA868C resulted in enhanced DP 2 receptor-mediated stimulation of CD11b expression. The balance between DP 1 and DP 2 receptors could determine the degree to which prostaglandin D 2 can activate eosinophils and may play a role in eosinophil recruitment in asthma. (Blood. 2001;98:1942-1948 
Introduction
Prostaglandins (PGs), formed by the actions of cyclooxygenases 1 and 2 on arachidonic acid, have biological effects on many types of cells through the actions of 8 known receptors. PGE 2 has 4 receptor subtypes (EP 1-4 receptors), whereas PGs D 2 , F 2␣ , I 2 , and thromboxane (TX) A 2 each have a single receptor (DP, FP, IP, and TP receptors, respectively). 1 The DP receptor is coupled positively to adenylyl cyclase through G s , 1 and this results in a strong inhibitory effect on platelet aggregation 2 as well as bronchodilator 3 and vasodilator 4 effects in humans. The DP receptor and lipocalin-type PGD synthase are both abundant in the central nervous system, where PGD 2 plays a role in regulating sleep 5 and pain perception. 6 Despite the DP receptor-mediated bronchodilator effect of PGD 2 , there is evidence that PGD 2 may contribute to the pathogenesis of asthma. Hematopoietic-type PGD 2 synthase is abundant in mast cells, 7 dendritic cells, 8 and certain subpopulations of T H 2 lymphocytes, 8, 9 all of which play critical roles in this disease. 10 PGD 2 is released from immunologically stimulated mast cells 11 and T H 2 cells, 9 and its levels in bronchoalveolar lavage fluid increase dramatically following allergen challenge of asthmatic subjects. 12 Recent evidence that DP receptor knockout mice are resistant to the pulmonary effects of antigen challenge provides further support for a role of PGD 2 in asthma. 13 Pulmonary infiltration of eosinophils and lymphocytes, levels of T H 2 lymphocyte-derived cytokines, and hyperresponsiveness were all dramatically lower in the DP receptordeficient mice compared with control wild-type mice. 13 The reduction in eosinophil recruitment is interesting in view of the key role played by these cells in the pathophysiology of asthma owing to their release of proinflammatory cytokines, bronchoconstrictor cysteinyl leukotrienes (LTs), degradative enzymes, and other factors. 14 Furthermore, in dogs, PGD 2 caused a rapid reduction in circulating eosinophil levels, 15 whereas tracheal superfusion of PGD 2 in vivo induced the recruitment of eosinophils but not neutrophils into the superfusate. 16 It is unclear from the above studies whether the in vivo effects of PGD 2 are due to direct effects on eosinophils or are caused by the release of mediators from other cells. However, PGD 2 has been reported to directly stimulate calcium mobilization and LTC 4 release in vitro in human eosinophils. 17 The stimulatory effects of PGD 2 on eosinophils are somewhat surprising, as this prostaglandin is thought to act via DP receptormediated stimulation of adenylyl cyclase. 1 A number of studies have clearly shown that agents that raise adenosine 3Ј,5Ј-cyclic monophosphate (cAMP) levels in eosinophils inhibit various responses, including LTC 4 release, chemotaxis, and degranulation. 18, 19 This raises the possibility that PGD 2 can activate eosinophils by a mechanism unrelated to the DP receptor. The objectives of the current study were to determine whether PGD 2 has a direct chemotactic effect on eosinophils and, if so, to investigate the hypothesis that this effect is mediated by a novel receptor for this compound.
Materials and methods

Materials
Prostaglandins and BW245C were purchased from Cayman Chemical (Ann Arbor, MI). BWA868C was kindly provided by Glaxo Wellcome (Stevenage, United Kingdom), and 5-oxo-6,8,11,14-eicosatetraenoic acid (5-oxo-ETE) was synthesized chemically. 20 N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)phallacidin (NBD-phallacidin) was obtained from Molecular Probes (Eugene, OR). Fluorescein isothiocyanate (FITC)-labeled mouse antihuman CD11b (Bear1) and the corresponding FITC-labeled isotype immunoglobulin G1 (IgG1) control antibody were purchased from BeckmanCoulter (Fullerton, CA). FITC-labeled mouse anti-human L-selectin (Leu-8), the corresponding control IgG2a antibody, and phycoerythrin (PE)-labeled mouse anti-human very late antigen 4 (VLA-4) were purchased from Becton Dickinson (San Jose, CA).
Preparation of blood cells
Unfractionated leukocytes were prepared by removal of red blood cells from whole blood, obtained from healthy human subjects, by treatment with Dextran T-500 (Amersham-Pharmacia Biotech, Piscataway, NJ) for 45 minutes at 4°C. 21 This preparation was used for measurements of CD11b and L-selectin. Granulocytes were prepared by centrifugation of red cell-depleted leukocytes over Ficoll-Paque (Amersham-Pharmacia Biotech), followed by removal of remaining red cells by hypotonic lysis as described previously. 21 This fraction was used for experiments on neutrophil chemotaxis. Purified eosinophils were obtained by treating granulocytes with anti-CD16-labeled paramagnetic microbeads (Miltenyi Biotec, Bergisch-Gladbach, Germany) and removing the labeled neutrophils on a column containing a steel matrix placed in a permanent magnet (MACS, Miltenyi Biotec). Eosinophils (95% Ϯ 4% pure) were obtained in the pass-through fraction 22 and were used for experiments evaluating chemotaxis, actin polymerization, and cAMP formation.
Measurement of chemotactic responses
Cell migration was measured as previously described 23 by means of 48-well microchemotaxis chambers (Neuro Probe, Cabin John, MD) and Sartorius cellulose nitrate filters (8-m pore size; 140-m thickness) (Neuro Probe). Agonists were added to the bottom well in a volume of 30 L phosphatebuffered saline (PBS) (137 mM NaCl, 2.7 mM KCl, 1.5 mM KH 2 PO 4 , and 8.1 mM Na 2 HPO 4 at a pH of 7.4) containing 1 mM CaCl 2 , 1 mM MgCl 2 , and 0.3% bovine serum albumin, whereas eosinophils or neutrophils (150 000 cells in 55 L RPMI containing 0.4% ovalbumin) were added to each of the top wells. Following incubation for 2 hours at 37°C, the filters were fixed with mercuric chloride and stained with hematoxylin and chromotrope 2R. 24 The numbers of cells on the bottom surfaces of the filters were counted in 5 different fields at a magnification of 400 ϫ for each incubation, each of which was performed in duplicate.
Measurement of actin polymerization
Eosinophil F-actin was measured by means of NBD-phallicidin, which binds strongly to F-actin, the polymerized form of actin, but not to unpolymerized G-actin. 25 Eosinophils (3 ϫ 10 5 cells in 260 L) were incubated with agonists for 20 seconds, followed by fixation with formaldehyde (30 L of a 37% solution) at room temperature for 15 minutes. F-actin was then stained by incubation with lysophosphatidylcholine (30 g in 15 L) and NBD-phallacidin (49 pmol in 6.2 L; final concentration, 0.15 M) overnight in the dark at 4°C. The cells were then centrifuged at 700g for 5 minutes and resuspended in PBS (0.5 mL). The fluorescence intensity of the stained eosinophils was quantified by flow cytometry with a Becton Dickinson Facscalibur instrument.
Measurement of surface expression of CD11b and L-selectin
CD11b and L-selectin were measured as described previously. 26 Unfractionated leukocytes (0.5 mL; 10 6 /mL) in PBS containing Ca ϩϩ and Mg ϩϩ were incubated with agonists for either 10 minutes (L-selectin) or 15 minutes (CD11b). The incubations were terminated by the addition of ice-cold Facsflow (Becton Dickinson) and centrifugation. Following incubation of the pellets for 10 minutes at 4°C with mouse plasma (5 L), the cells were incubated for 30 minutes at 4°C with PE-labeled anti-VLA-4 (5 L) along with an FITC-labeled antibody (10 L) to either CD11b or L-selectin or the appropriate isotype-matched control FITC-labeled antibody. After incubation with Optilyse C (0.25 mL) (Beckman-Coulter) for 15 minutes, the cells were centrifuged and fixed in 1% formaldehyde in PBS (0.4 mL). The distribution of fluorescence intensities among 60 000 cells was measured by flow cytometry. Eosinophils were gated out on the basis of their granularity (high side scatter) and labeling with anti-VLA-4 (PE fluorescence). CD11b or L-selectin was then measured in the eosinophil region on the basis of fluorescence due to FITC as previously described. 26 
Measurement of cAMP levels
Purified eosinophils (5 ϫ 10 5 ) in 100 L PBS were preincubated with the phosphodiesterase-4 inhibitor rolipram (10 M) (Sigma Chemical, St Louis, MO) for 15 minutes at 37°C and incubated with prostanoids for a further 15 minutes. In certain experiments, BWA868C was added 2 minutes prior to the addition of prostanoids. Platelets were purified as described previously 27 and resuspended in PBS (without rolipram). Aliquots (3 ϫ 10 7 platelets in 100 L) were incubated with prostanoids for 2 minutes at 37°C. In both cases, the reaction was terminated with cold ethanol (300 L), and the precipitated proteins were removed by centrifugation (600g for 15 minutes). We measured cAMP in the supernatants using a competitive protein-binding radiometric assay (Diagnostic Products, Los Angeles, CA) according to the manufacturer's instructions.
Results
PGD 2 is a potent and selective eosinophil chemoattractant
We first investigated the effects of PGD 2 on the migration of human eosinophils, which were purified from a polymorphonuclear cell fraction by removal of neutrophils with iron-labeled anti-CD16. 22 Chemotactic effects were evaluated by means of a modified Boyden chamber assay in which cells that had migrated through a nitrocellulose filter were stained and counted. As a positive control, we used 5-oxo-ETE, which we have shown to be the most efficacious eosinophil chemoattractant among lipid mediators, inducing a maximal response about 3 times greater than that of platelet-activating factor (PAF) 23 and about 50% higher than the chemokine eotaxin. 26 The present experiments indicate that PGD 2 is a potent eosinophil chemoattractant with a median effective concentration (EC 50 ) of 5 nM ( Figure 1A ). Although the maximal response of PGD 2 is about one third that of 5-oxo-ETE, it is very similar to that of PAF. 23 Furthermore, unlike 5-oxo-ETE 28 and PAF, 29 PGD 2 does not have an appreciable effect on neutrophil migration ( Figure 1B ), which puts it in a unique position among lipid mediators as a selective eosinophil chemoattractant. This selective effect on eosinophil activation is reminiscent of the potent eosinophil chemoattractant eotaxin. 30 The chemotactic effects of PGD 2 on eosinophils are not mediated by receptors for other prostanoids
The stimulatory effect of PGD 2 on eosinophils raised the question of whether it is acting via the classical DP receptor, which signals through G s -mediated stimulation of adenylyl cyclase, as this would be expected to inhibit, rather than induce, eosinophil activation. 18, 19 As stimulatory effects of PGD 2 have often been attributed to other prostanoid receptors, including FP 31, 32 and TP 33 ,34 receptors, we tested the effects of PGF 2␣ , PGE 2 , and U46619, a TP receptor agonist, on eosinophil migration. None of these compounds exhibited significant chemoattractant effects on these cells, with the possible exception of PGF 2␣ at the highest concentration tested ( Figure 1A ). These results clearly indicate that PGD 2 does not induce eosinophil migration by interacting with receptors for other prostanoids.
PGD 2 selectively stimulates CD11b expression on eosinophils
We also investigated the effects of PGD 2 on other processes involved in the infiltration of eosinophils into tissues, including expression of the cellular adhesion molecule CD11b, which is important for the adherence of eosinophils to endothelial cells. 35 Measurement of CD11b permitted more extensive experiments to be conducted because this does not require purification of eosinophils, which are present in blood in relatively small numbers. With the use of flow cytometry, it is possible to make simultaneous measurements on both eosinophils and neutrophils with the use of relatively small numbers of unfractionated leukocytes, while at the same time minimizing the artifactual activation of cells that occurs during purification. 26 Eosinophils were gated out from other cells on the basis of high side scatter owing to their granularity and labeling with PE-labeled anti-VLA-4 as shown by the dot plot in the inset to Figure 2A , and were readily distinguishable from neutrophils ( Figure 2B , inset). PGD 2 (1 M) increased the expression of CD11b on eosinophils to about the same extent as an identical concentration of 5-oxo-ETE (Figure 2A ). In contrast, PGD 2 had only a very small effect on neutrophil expression of CD11b, whereas 5-oxo-ETE strongly stimulated its expression on these cells ( Figure 2B ).
Concentration-response curves for the effects of PGD 2 and other eicosanoids on CD11b expression by eosinophils are shown in Figure 3A . PGD 2 (EC 50 , 5 nM) has a potency similar to that of 5-oxo-ETE (EC 50 , 7.5 nM) and a maximal response about 25% lower. PGE 2 and the TP receptor agonist U46619 did not affect CD11b expression appreciably, whereas PGF 2␣ had detectable effects only at concentrations of 100 nM or above and appeared to be about 2 orders of magnitude less potent than PGD 2 ( Figure 3A) . Similarly, the IP receptor agonist carbaprostacyclin was also without effect (data not shown). PGD 2 had very little effect on CD11b expression by neutrophils ( Figure 3B ), unlike 5-oxo-ETE, which was a strong inducer of this response in both neutrophils and eosinophils.
PGD 2 induces shedding of L-selectin from eosinophils but not neutrophils
Activation of granulocytes by chemoattractants often results in the shedding of L-selectin owing to the action of a metalloproteinase. 36 Intact L-selectin was measured on eosinophils and neutrophils by Figure 2 . The results are expressed as percentages (Ϯ SE) of the maximal responses to 5-oxo-ETE for eosinophils (98% Ϯ 9% above control) and neutrophils (114% Ϯ 21% above control) after subtraction of control values. Experiments were performed on cells from the numbers of different individuals indicated for PGD2 (F; n ϭ 21) 5-oxo-ETE (E, 5o-ETE; n ϭ 10), PGF2␣ (OE; n ϭ 3), PGE2 (ƒ; n ϭ 3), and U46619 (Ⅺ; n ϭ 3).
gating out these cells by means of flow cytometry as discussed above for CD11b. PGD 2 induced L-selectin shedding from eosinophils, although to a lesser extent than 5-oxo-ETE ( Figure 4A ). PGE 2 did not appreciably affect L-selectin on eosinophils. In contrast, PGD 2 , like PGE 2 , had no effect on L-selectin shedding in neutrophils, whereas 5-oxo-ETE strongly stimulated this response ( Figure 4B ).
PGD 2 stimulates actin polymerization in eosinophils
Migration of leukocytes into tissues involves dramatic changes in cell shape that are dependent on actin polymerization. PGD 2 strongly induced the formation of polymerized F-actin in purified eosinophils with an EC 50 (6.5 nM) and maximal response very similar to those of 5-oxo-ETE (EC 50 , 10 nM) ( Figure 5 ). This is quite interesting in view of our recent findings that 5-oxo-ETE induces a significantly stronger actin polymerization response in eosinophils than a variety of other chemoattractants, including PAF 37 and eotaxin. 26 In contrast to PGD 2 , PGE 2 had no effect on actin polymerization, whereas PGF 2␣ was active only at the highest concentration tested (1 M).
Eosinophils possess DP receptors
As it was not known whether eosinophils possess DP receptors, we investigated the effects of PGD 2 and the highly selective DP receptor agonist BW245C on cAMP formation in these cells. BW245C has been reported to be slightly more potent than PGD 2 38 and to have over 300 times higher affinity for DP receptors compared with other prostanoid receptors. 32 Both PGD 2 and BW245C elevated cAMP levels in purified eosinophils, with the latter compound being slightly more potent ( Figure 6A ), clearly demonstrating the presence of classic G s -coupled DP receptors on these cells. The effects of these compounds were comparable to that of PGE 2 , which stimulates adenylyl cyclase by interacting with EP 2 and EP 4 receptors. The effects of PGD 2 and BW245C on eosinophils were very similar to their effects on human platelets, which are known to possess DP receptors 1 ( Figure 6B ). Consistent with previous reports, 32 PGJ 2 was equipotent with PGD 2 in stimulating cAMP formation in platelets, whereas BW245C was more potent. In contrast, the PGD 2 metabolite 13,14-dihydro-15-oxo-PGD 2 had no effect on cAMP formation in platelets.
The effects of PGD 2 on eosinophil migration and CD11b expression are not mediated by DP receptors
The relative potencies of the above compounds on CD11b expression in eosinophils were quite different from their potencies in stimulating platelet adenylyl cyclase. In contrast to its potent effects on platelet cAMP levels, BW245C has virtually no effect on CD11b expression ( Figure 7A ). PGJ 2 , which is equipotent to PGD 2 in stimulating platelet adenylyl cyclase, is only about one tenth as potent in stimulating eosinophil CD11b expression. Furthermore, 13,14-dihydro-15-oxo-PGD 2 was nearly as potent as PGD 2 in stimulating CD11b expression, despite its lack of activity in platelets. The relative potencies of PGD 2 , PGJ 2 , and BW245C in stimulating eosinophil migration were nearly identical to those for simulation of CD11b expression ( Figure 7B ). The striking differences in the structure-activity relationships for PGD 2 -induced stimulation of DP receptor-dependent cAMP formation and stimulation of CD11b and chemotactic responses provide compelling evidence that the latter effects are mediated by a novel stimulatory PGD 2 receptor on eosinophils. The existence of both stimulatory and inhibitory PGD 2 receptors on eosinophils raised the possibility that these receptors could interact to regulate eosinophil responses to PGD 2 , with classic DP receptors serving to limit PGD 2 -induced eosinophil activation. To test this hypothesis, we used the highly selective DP receptor antagonist BWA868C. 32, 39 Although BWA868C alone had no effect on CD11b expression at concentrations up to 1 M, it strongly stimulated PGD 2 -induced CD11b expression, increasing the maximal response by about 60% (P Ͻ .001) ( Figure 8A ). The EC 50 for PGD 2 appeared to be reduced slightly, from 8 nM (PGD 2 alone) to 4 nM, but this difference was not significant. In contrast, BWA868A (100 nM) strongly inhibited PGD 2 -induced cAMP formation in eosinophils ( Figure 8B ). The enhanced CD11b response to PGD 2 in the presence of the DP receptor antagonist suggests that PGD 2 -induced stimulation of adenylyl cyclase can attenuate its effect on eosinophil activation, mediated by the novel PGD 2 receptor. Furthermore, the failure of the DP receptor antagonist to inhibit PGD 2 -stimulated CD11b expression provides additional evidence for the existence of a second PGD 2 receptor.
Discussion
The present study clearly demonstrates the presence of a novel PGD 2 receptor on human eosinophils that results in activation of these cells. This is supported by several lines of evidence: (1) PGD 2 stimulates actin polymerization, CD11b expression, L-selectin shedding, and chemotaxis in eosinophils; (2) these effects are not mediated by receptors for other prostanoids, since they cannot be reproduced by agonists for these receptors, and (3) these effects are not mediated by the classic DP receptor, as they are neither induced by the potent DP receptor agonist BW245C nor inhibited by the potent DP receptor antagonist BWA868C. Furthermore, the PGD 2 metabolite 13,14-dihydro-15-oxo-PGD 2 is only slightly less potent than PGD 2 in stimulating CD11b expression on eosinophils but has no effect on DP receptor-mediated stimulation of cAMP formation in platelets. The specificity of the novel receptor for PGD 2 -related ligands (PGD 2 equals or exceeds 13,14-dihydro-15-oxo-PGD 2 , which equals or exceeds PGJ 2 , which is much greater than BW245C) is quite different from that of the classic DP receptor (BW245C equals or exceeds PGD 2 ϭ PGJ 2 , which is much greater than 13,14-dihydro-15-oxo-PGD 2 ). It does not interact appreciably with ligands for EP (PGE 2 ), IP (carbaprostacyclin), or TP (U46619) receptors. It would seem likely that PGF 2␣ has weak activity at the novel PGD 2 receptor, as it can activate eosinophils with about 1% of the potency of PGD 2 . It would seem unlikely that this is due to activation of FP receptors because of the low potency of PGF 2␣ in activating eosinophils. Because of the specificity of this novel receptor for PGD 2 , we propose the designation DP 2 receptor. The classic G s -coupled DP receptor would then be designated as the DP 1 receptor.
In addition to DP 2 receptors, we have shown for the first time that eosinophils also possess classic DP 1 receptors coupled to adenylyl cyclase. These receptors display the same specificity for PGD 2 -like compounds as the platelet DP 1 receptor, as shown in the present study and various other studies. 32, 38 However, the magnitude of the cAMP response appeared to be less than that observed for platelets, possibly owing to limitations of cell numbers and rapid metabolism of cAMP by phosphodiesterase-4, which is known to be present in eosinophils. 40 It was necessary to inhibit this enzyme with rolipram to observe the effect of PGD 2 on cAMP levels in eosinophils, but this was not necessary with platelets. The presence of both DP 1 and DP 2 receptors on eosinophils could explain previous reports that PGD 2 has both stimulatory and inhibitory effects on these cells. 41 The ability of PGD 2 to activate eosinophils while at the same time stimulating adenylyl cyclase is intriguing, as increased cAMP levels would be expected to attenuate eosinophil responses. The phosphodiesterase-4 inhibitor rolipram has been shown to inhibit eosinophil migration and CD11b expression in response to eotaxin, 42 PAF, 18, 43, 44 and C5a. Stimulation of adenylyl cyclase with forskolin 44 or isoproterenol 43 or addition of dibutyryl cAMP 43 had similar effects. This raised the possibility that PGD 2 could have opposing actions on eosinophils and that its stimulatory effect could be blunted by concomitant stimulation of adenylyl cyclase, especially at higher concentrations of PGD 2 . This hypothesis was confirmed by the finding that blocking DP 1 receptor-mediated cAMP formation in eosinophils with BWA868C resulted in a markedly enhanced DP 2 receptor-mediated CD11b response to PGD 2 . Thus, it would appear that DP 1 receptors could serve to negatively regulate DP 2 receptor-mediated responses in eosinophils ( Figure 9 ). The balance between inhibitory DP 1 and stimulatory DP 2 receptors is likely to determine the final response of these cells to PGD 2 . A reduction in expression of DP 1 receptors, for example, could enhance PGD 2 -mediated stimulation of eosinophils, which could be important in diseases associated with eosinophil infiltration, such as asthma.
In contrast to its stimulatory effects on eosinophils, PGD 2 appears to have an inhibitory effect on neutrophils. In the present study, we found that PGD 2 induces little or no migration, CD11b expression, or L-selectin shedding in these cells. On the other hand, PGD 2 has been reported to stimulate cAMP formation and to inhibit PAF responses in neutrophils. 45 This suggests that neutrophils possess DP 1 receptors, but lack appreciable numbers of DP 2 receptors. It is possible that the opposite actions of PGD 2 on neutrophils and eosinophils could further contribute to the selective accumulation of eosinophils in some conditions, such as asthma.
Although the effects of stimulation of DP 1 receptors on neutrophils and eosinophils would be considered to be antiinflammatory, it is clear that the overall role of DP 1 receptors in inflammation is much more complex, as it also appears to be involved in promoting inflammation. Deletion of this receptor in mice markedly reduced the pulmonary eosinophilia and hyperresponsiveness that occurred following antigen challenge of control animals. This was accompanied by reduced levels of the T H 2 cytokines interleukin (IL)-4, IL-5, and IL-13 but no change in the T H 1 cytokine interferon-␥ or in IgE levels. 13 These results suggest that in vivo the DP 1 receptor contributes to eosinophil infiltration following antigen challenge. Because the DP 1 receptor appears to attenuate eosinophil responses in vitro, it would appear likely that the stimulatory effect of this receptor in vivo is indirect, possibly mediated by increased production of the T H 2 cytokines IL-4 and IL-5, which are known to be involved in eosinophil recruitment. 30 Alternatively, the possibility that the lack of the DP 1 receptor in these mice favored the development of a compensatory mechanism that could attenuate eosinophil responses cannot be ruled out.
In contrast to the DP 1 receptor, the DP 2 receptor would appear to have a strictly proinflammatory effect, at least on the basis of its function in eosinophils. The proinflammatory and anti-inflammatory effects of PGD 2 underline the complex roles of prostanoids in inflammation and the growing debate on their proinflammatory and anti-inflammatory effects. 46, 47 PGD 2 is the second prostanoid to have multiple receptors that are clearly distinct from one another. The actions of PGE 2 are mediated by 4 different receptors, 2 of which (EP 2 and EP 4 ) act by stimulation of adenylyl cyclase, whereas the others act by inhibition of adenylyl cyclase (EP 3 ) and by increasing cytosolic calcium levels (EP 1 ). 1 The presence of these multiple receptors has explained the often-opposing actions of PGE 2 on various cells and tissues. Similarly, the existence of a second PGD 2 receptor may clarify some of the discrepant reports in the literature documenting various effects of PGD 2 that were not readily explained by its interaction with DP 1 receptors accompanied by activation of adenylyl cyclase. 48 Some of these effects may be due to interaction with receptors for other prostanoids, as PGD 2 has a relatively high affinity for FP receptors 32, 49 and PGD 2 -mediated bronchoconstriction has been reported to be due to stimulation of TP receptors. 33, 34 In contrast, some other effects of PGD 2 , such as those on epithelial cell ion transport, 50 are difficult to explain on the basis of classic prostanoid receptors and may be due to stimulation of DP 2 receptors.
After completion of the present study, Hirai et al 51 reported that PGD 2 is specifically bound by CRTH2 (chemoattractant receptorhomologous molecule expressed on T H 2 cells), an orphan receptor previously identified as a marker for T H 2 cells, 52 which was also shown to be present on basophils and eosinophils. 53 PGD 2 was found to induce migration of eosinophils, basophils, and T H 2 cells that was blocked by an antibody to CRTH2. 51 The binding affinities of various ligands for K562 cells transfected with CRTH2 51 are similar to their abilities to stimulate DP 2 receptor-mediated responses in eosinophils, as found in the present study, suggesting that these 2 receptors are identical. Owing to the lack of sufficient numbers of human eosinophils, we were unable to conduct binding studies, but we have shown that, in addition to chemotaxis, PGD 2 can induce a variety of other responses in these cells, including actin polymerization, CD11b expression, and L-selectin shedding. Moreover, the present study demonstrates an interaction between inhibitory DP 1 receptors and stimulatory DP 2 receptors, resulting in attenuated DP 2 -mediated responses to PGD 2 .
In conclusion, we have shown that eosinophils possess both a novel DP 2 receptor, which is responsible for the chemoattractant effect of PGD 2 , and the classic DP 1 receptor, which appears to play a regulatory role in these cells. The balance between these receptors is likely to regulate the response of these cells to PGD 2 and may be important in asthma. The role of DP 1 receptors is obviously complex, as they appear to contribute to eosinophil infiltration indirectly through effects on T H 2 cell cytokine production. 13 The direct and indirect effects of PGD 2 on eosinophil migration as well as its strategic location in mast cells and antigen presenting cells suggest an important role for this prostaglandin in asthma. For personal use only. on September 14, 2017. by guest www.bloodjournal.org From
